Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yuriko Ito Sasahara"'
Autor:
Yuriko (Ito) Sasahara, Hiroto Narimatsu, Syuhei Suzuki, Tadahisa Fukui, Hideyuki Sato, Nakao Shirahata, Takashi Yoshioka
Publikováno v:
Clinical Medicine Insights: Case Reports, Vol 2014, Iss 7, Pp 59-61 (2014)
Externí odkaz:
https://doaj.org/article/d44f886cd05c4ae98ae0228d200223d9
Autor:
TAKASHI YOSHIOKA, MASANOBU TAKAHASHI, YASUHIRO SAKAMOTO, AKIRA OKITA, TADAHISA FUKUI, YASUKO MURAKAWA, YOSHIAKI SHINDO, HIROO IMAI, HISATSUGU OHORI, HIDEKAZU SHIROTA, NATSUKO CHIBA, YURIKO (ITO) SASAHARA, TAKASHI NOMURA, NORIMASA FUKUSHIMA, TAKUHIRO YAMAGUCHI, HIDEKI SHIMODAIRA, CHIKASHI ISHIOKA
Publikováno v:
Anticancer research. 42(4)
This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1.This single-arm, open-label, multicenter, phase II study was conducted by Tohoku Clinical Oncology Research a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d611359f1db4a9f2450e610bcac80f
https://pubmed.ncbi.nlm.nih.gov/35347022
https://pubmed.ncbi.nlm.nih.gov/35347022
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-3 (2019)
Background Metastatic tumors in the orbit, especially from gastric cancer, are rare. We present a rare case of extraocular muscle metastasis from gastric cancer and raise consideration of metastasis to extraocular muscle as a differential diagnosis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0433fec33120da8bbf52125be229c22e
http://link.springer.com/article/10.1186/s13256-019-2031-x
http://link.springer.com/article/10.1186/s13256-019-2031-x
Publikováno v:
International Journal of Clinical Oncology. 21:1004-1013
Recently, the approval of some molecularly targeted drugs has been questioned, due to differing opinions on their risks and benefits. The approval process remains a challenge in regulatory science. We analyzed the molecularly targeted drugs listed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179f7cc30b8f6348dce86b547be3f34c
https://doi.org/10.1007/s10147-016-0980-2
https://doi.org/10.1007/s10147-016-0980-2
Autor:
Takashi Yoshioka, Isao Kubota, Takeo Kato, Yoshiyuki Ueno, Ryo Kawasaki, Sho Nakamura, Ri Sho, Hidetoshi Yamashita, Akira Fukao, Takamasa Kayama, Yuriko Ito Sasahara, Hiroto Narimatsu
Publikováno v:
Cancer Science
The number of cancer survivors is increasing; however, optimal health management of cancer survivors remains unclear due to limited knowledge. To elucidate the risk of non-communicable diseases, and the effect of lifestyle habits on risk of non-commu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92eab53a79e226202eaa71c0220cede8
https://doi.org/10.1111/cas.12811
https://doi.org/10.1111/cas.12811
Autor:
Yuriko Ito Sasahara, Takashi Yoshioka, Mayumi Ichikawa, Misako Miwa, Hiroyuki Takeda, Mayumi Yamakawa, Tadahisa Fukui, Kenji Nemoto, Sho Nakamura, Shuhei Suzuki
Publikováno v:
Internal Medicine
Objective The influence of cancer boards with respect to the treatment decisions regarding chemotherapy remains to be elucidated. In the present study, we investigated the cases that presented at our institutional cancer boards, to assess the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b9078a7cac2258cb465fd371a76bd0b
https://pubmed.ncbi.nlm.nih.gov/27803404
https://pubmed.ncbi.nlm.nih.gov/27803404
Autor:
Nakao Shirahata, Takashi Yoshioka, Yuriko Ito Sasahara, Tadahisa Fukui, Hideyuki Sato, Syuhei Suzuki, Hiroto Narimatsu
Publikováno v:
Clinical Medicine Insights. Case Reports
Clinical Medicine Insights: Case Reports, Vol 2014, Iss 7, Pp 59-61 (2014)
Clinical Medicine Insights: Case Reports, Vol 7 (2014)
Clinical Medicine Insights: Case Reports, Vol 2014, Iss 7, Pp 59-61 (2014)
Clinical Medicine Insights: Case Reports, Vol 7 (2014)
Erlotinib is an approved drug for the treatment of advanced pancreatic cancer; however, its survival benefit is small and its cost is high, and the decision to use the drug may often be personalized according to the patient's background. A 72-year-ol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d2e15a212a0413ff2e61df5ecfaefd6
http://europepmc.org/articles/PMC4116360
http://europepmc.org/articles/PMC4116360
Autor:
Yuriko Ito Sasahara, Sho Nakamura, Tadahisa Fukui, Kaname Watanabe, Hiroto Narimatsu, Shuhei Suzuki, Takashi Yoshioka, Hiroyuki Takeda
Publikováno v:
Annals of Oncology. 27:vii75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfcc294099e1c590c21b0074790c651e
https://doi.org/10.1093/annonc/mdw521.002
https://doi.org/10.1093/annonc/mdw521.002